Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Li, Samuel Q ^a   Cheuk, Adam T ^a   Shern, Jack F ^a   Song, Young K ^a   Hurd, Laura ^a   Liao, Hongling ^a   Wei, Jun S ^a   Khan, Javed ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; PONATINIB; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; IC 50; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; WILD TYPE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; IMIDAZOLES; MICE; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDAZINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RHABDOMYOSARCOMA; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN;

EID: 84885029891     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076551     Document Type: Article

References (32)

1. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA, (2009) Trends in Childhood Rhabdomyosarcoma Incidence and Survival in the United States, 1975-2005. Cancer 115: 4218-4226.
2. Malempati S, Hawkins DS, (2012) Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft-tissue Sarcoma committee experience and rationale for current COG studies. Pediatric Blood & Cancer 59: 5-10.
3. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, et al. (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21: 78-84.
4. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, et al. (1993) Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 3: 113-117.
5. Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K, et al. (1989) A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci U S A 86: 7480-7484.
6. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, et al. (2000) P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 35: 96-103.
7. Stratton MR, Fisher C, Gusterson BA, Cooper CS, (1989) Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 49: 6324-6327.
8. Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, et al. (2012) Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 18: 748-757.
9. Taylor JGt, Cheuk AT, Tsang PS, Chung JY, Song YK, et al. (2009) Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 119: 3395-3407.
10. Zhao P, Caretti G, Mitchell S, McKeehan WL, Boskey AL, et al. (2006) Fgfr4 is required for effective muscle regeneration in vivo- Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. Journal of Biological Chemistry 281: 429-438.
11. Marics I, Padilla F, Guillemot JF, Scaal M, Marcelle C, (2002) FGFR4 signaling is a necessary step in limb muscle differentiation. Development 129: 4559-4569.
12. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Medicine 7: 673-679.
13. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH,et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 70: 6497-6508.
14. O'Hare T, Shakespeare WC, Zhu XT, Eide CA, Rivera VM, et al. (2009) AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. Cancer Cell 16: 401-412.
15. Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, et al. (2011) Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies. Molecular Cancer Therapeutics 10: 1028-1035.
16. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, et al. (2012) Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11: 690-699.
17. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, et al. (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nature Medicine 10: 175-181.
18. Hu K, Lee C, Qiu D, Fotovati A, Davies A, et al. (2009) Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 8: 3024-3035.
19. Thuault S, Hayashi S, Lagirand-Cantaloube J, Plutoni C, Comunale F, et al. (2012) P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness. Oncogene.
20. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, et al. (2011) Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333: 1039-1043.
21. Stauffer JK, Orentas RJ, Lincoln E, Khan T, Salcedo R, et al. (2012) High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery. Cancer Invest 30: 343-363.
22. Paulson V, Chandler G, Rakheja D, Galindo RL, Wilson K, et al. (2011) High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 50: 397-408.
23. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, et al. (2006) Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 66: 6936-6946.
24. Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, et al. (2012) FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 18: 3780-3790.
25. Klint P, Claesson-Welsh L, (1999) Signal transduction by fibroblast growth factor receptors. Front Biosci 4: D165-177.
26. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, et al. (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389-4400.
27. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, et al. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774-4782.
28. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, et al. (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105: 2941-2948.
29. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, et al. (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11: 3633-3641.
30. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, et al. (2007) PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6: 3158-3168.
31. Fancelli D, Moll J, Varasi M, Bravo R, Artico R, et al. (2006) 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 49: 7247-7251.
32. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, et al. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63: 7345-7355.